12,973 Shares in Eli Lilly and Company (LLY) Purchased by Institute for Wealth Management LLC.

Institute for Wealth Management LLC. acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 12,973 shares of the company’s stock, valued at approximately $1,063,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Accredited Investors Inc. lifted its holdings in Eli Lilly and by 0.4% during the second quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock valued at $268,000 after purchasing an additional 14 shares in the last quarter. Northwest Quadrant Wealth Management LLC lifted its holdings in Eli Lilly and by 0.5% during the first quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock valued at $290,000 after purchasing an additional 19 shares in the last quarter. Oakworth Capital Inc. lifted its holdings in Eli Lilly and by 0.3% during the second quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock valued at $552,000 after purchasing an additional 20 shares in the last quarter. Sfmg LLC lifted its holdings in Eli Lilly and by 0.5% during the second quarter. Sfmg LLC now owns 4,258 shares of the company’s stock valued at $350,000 after purchasing an additional 20 shares in the last quarter. Finally, Jackson Grant Investment Advisers Inc. lifted its holdings in Eli Lilly and by 0.7% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,647 shares of the company’s stock valued at $300,000 after purchasing an additional 24 shares in the last quarter. 76.61% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have issued reports on LLY shares. Credit Suisse Group downgraded shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and increased their price objective for the company from $84.23 to $88.00 in a report on Tuesday, October 10th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $103.00 price objective on shares of Eli Lilly and in a report on Thursday, August 31st. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 price objective on the stock in a report on Thursday, October 26th. Jefferies Group LLC reaffirmed a “buy” rating and set a $89.00 price objective (down from $94.00) on shares of Eli Lilly and in a report on Thursday, August 24th. Finally, BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the company a “sell” rating in a report on Wednesday, November 1st. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the stock. Eli Lilly and presently has an average rating of “Hold” and a consensus price target of $89.76.

WARNING: “12,973 Shares in Eli Lilly and Company (LLY) Purchased by Institute for Wealth Management LLC.” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/11/20/12973-shares-in-eli-lilly-and-company-lly-purchased-by-institute-for-wealth-management-llc.html.

Shares of Eli Lilly and Company (LLY) opened at $82.89 on Monday. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $89.09. The stock has a market cap of $91,269.77, a PE ratio of 20.27, a P/E/G ratio of 1.83 and a beta of 0.34. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The firm had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. During the same period last year, the business earned $0.88 earnings per share. Eli Lilly and’s revenue was up 9.0% compared to the same quarter last year. analysts predict that Eli Lilly and Company will post 4.21 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.51%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s payout ratio is currently 98.58%.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 205,000 shares of Eli Lilly and stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total transaction of $17,796,050.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the sale, the senior vice president now owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 772,003 shares of company stock valued at $64,837,441. 0.20% of the stock is owned by company insiders.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply